中國agreementsDesignExamination GuidePatent Law
2023年1月4日

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

by
黃惠盈女士
黃幸兒女士
車李曉芸女士

Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO).

Up until this moment, the World Intellectual Property Organization (WIPO) and the CNIPA1 have been silent on whether a Hong Kong design applicant without a habitual residence or business office in mainland China would be eligible to file a Hague international design application with the CNIPA as a RO.

We recently brought this matter forward to the CNIPA. The CNIPA confirmed that Hong Kong applicants without a habitual residence or business office in mainland China are not eligible to file such type of application with the CNIPA.

A Hague application currently does not cover Hong Kong nor Macao

Although China is included in the current list of the contracting parties of the Hague Agreement, Hong Kong SAR and Macao SAR – both separate jurisdictions having distinct Basic Laws from the People Republic of China – are not included.

This means that Hong Kong and Macao design applicants must file independent design applications in these two regions.

Despite the current situation, things may change in the future. China’s “instrument of accession” (legal document indicating China’s agreement to join the Hague Agreement) provides room for change, stating that the current situation stands “until otherwise notified by the Government of the People’s Republic of China”2. This means that China has already included provisions allowing it to provide notification of changes regarding Hong Kong and Macao in the future.

Stay tuned for more upcoming articles about the other changes in the proposed Patent Examination Guidelines.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

  1. https://www.wipo.int/hague/en/
    https://www.wipo.int/hague/memberprofiles/selectmember#/
    https://www.wipo.int/hague/en/news/2022/news_0005.html
    https://www.wipo.int/treaties/en/notifications/hague/treaty_hague_146.html
    https://wipolex.wipo.int/en/treaties/ShowResults?search_what=C&treaty_id=9
    https://www.cnipa.gov.cn/col/col2893/index.html
    https://www.cnipa.gov.cn/art/2022/10/31/art_75_180016.html
    https://www.cnipa.gov.cn/module/download/downfile.jsp?classid=0&showname=附件1:《专利审查指南修改草案(再次征求意见稿)》修改对照表.pdf&filename=dab071af523943b49eaf1114a84b6234.pdf ↩︎
  2. https://www.wipo.int/hague/en/news/2022/news_0005.html ↩︎

其他文章

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

2023年11月10日
On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see […]

Breaking: China Released New Implementation Measures for the New Patent Linkage System

2021年7月14日
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

2023年4月12日
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]

我們過去活動

Top crossarrow-right